Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th
Rhea-AI Summary
Envoy Medical (NASDAQ: COCH) announced that CEO Brent Lucas will present at the Planet MicroCap Conference Las Vegas 2026 from June 16-18 at the Bellagio Hotel & Casino.
The presentation is scheduled for Wednesday, June 17, 2026 at 11:00 A.M. PT in Track 7 - Donatello 3, with a webcast available.
Positive
- None.
Negative
- None.
News Market Reaction – COCH
In the Jun 4 session, COCH gained 1.82%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 20 | IP expansion | Positive | -0.1% | New patents granted expanding fully implanted hearing technology portfolio. |
| May 11 | FDA progress & financing | Positive | -0.2% | Q1 results plus pivotal trial progress and upsized public offering details. |
| Apr 28 | Clinical data update | Positive | -3.0% | Interim six-month data from first 10 Acclaim pivotal trial patients. |
| Apr 22 | Trial milestone | Positive | -4.3% | All 56 patients in pivotal Acclaim trial completed Activation Visits. |
| Apr 16 | Board appointment | Positive | -2.6% | New director with prior exits advising Acclaim commercialization. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational and clinical updates have been followed by negative 24-hour price reactions, indicating a pattern of selling into good news.
Over the past few months, Envoy Medical has reported several milestones: new patents in Australia and Europe, pivotal trial progress toward FDA PMA submission for the fully implanted Acclaim cochlear implant, and interim data showing improved word recognition with no study-defined serious adverse events. It also completed enrollment and activation for all 56 pivotal-trial patients and added an experienced director. Despite these developments, each announcement saw a negative 24-hour price reaction, framing today’s conference update against a backdrop of consistent post-news weakness.
AI-generated analysis. How Rhea-AI works. Not financial advice.
White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV.
Planet MicroCap Las Vegas 2026
Dates: June 16-18, 2026
Location: Bellagio Hotel & Casino, Las Vegas, NV
Booth: #410
Presentation Day and Time: Wednesday, June 17, 2026, at 11:00 A.M. PT
Presentation Location: Track 7 - Donatello 3
Webcast: Viewable here
The Company will be participating in one-on-one investor meetings throughout the event. For more information about the conference, or to schedule a meeting with the Envoy Medical management team, please contact KCSA Strategic Communications at Envoy@kcsa.com.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300016